Acalabrutinib (Acala) vs Idelalisib plus Rituximab (IdR) or Bendamustine plus Rituximab (BR) in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): ASCEND Final Results
Safety of Acalabrutinib (Acala) Monotherapy in Hematologic Malignancies: Pooled Analysis From Clinical Trials
Acalabrutinib (Acala) in Treatment-Naïve Chronic Lymphocytic Leukemia: Mature Results From Phase 2 Study Demonstrating Durable Remissions and Long-Term Tolerability
The shift in therapies for the treatment of chronic lymphocytic leukemia (CLL) patients in the US Veterans Health Administration (VHA) from 2013-2018
Capivasertib and paclitaxel in first-line treatment of patients with metastatic triple-negative breast cancer: A Phase III trial (CAPItello-290)
ProCAID: A randomised double blind phase II clinical trial of capivasertib (C) in combination with docetaxel and prednisolone chemotherapy (DP) in metastatic castration resistant prostate cancer (mCRPC)
Results from a Phase I, Open-Label study of ceralasertib (AZD6738), DNA Damage Repair/Novel Anti-cancer Agent, in combination with weekly paclitaxel, in refractory cancer (NCT02630199)
DUETTE: A randomized phase II study to assess a second maintenance treatment with olaparib (ola) or ola+ceralasertib (cer), in patients (pts) with platinum sensitive relapsed (PSR) epithelial ovarian cancer who have previously received PARP inhibitor
Predicting overall survival (OS) and overall response (OR) following durvalumab treatment in patients with multiple cancer types using a hybrid modeling strategy
Efficacy, tolerability, and biologic activity of a novel regimen of tremelimumab (T) in combination with durvalumab (D) for patients (pts) with advanced hepatocellular carcinoma (aHCC)
First-line durvalumab plus platinum-etoposide in extensive-stage (ES)-SCLC (CASPIAN): Impact of brain metastases on treatment patterns and outcomes
Molecular biomarkers identify patients (pts) who may benefit from durvalumab (D; anti-PD-L1) ± tremelimumab (T; anti-CTLA-4) in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) from HAWK and CONDOR studies
Plasma-based tumor mutational burden (bTMB) as predictor for survival in phase 3 EAGLE study: durvalumab (D) ± tremelimumab (T) vs chemotherapy (CT) in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) after platinum failure
Actionable policy barriers for receiving standard of care treatment among unresected stage III non-small cell lung cancer patients in the United States
Concurrent chemoradiation therapy is associated with improved survival among unresected stage III non-small cell lung cancer patients in the United States
What constitutes high-quality NSCLC care? Overarching quality considerations for improving NSCLC care at US cancer centers.
A Phase 1 Study of mRNA-2752, a Lipid Nanoparticle Encapsulating mRNAs Encoding Human OX40L, IL-23, and IL-36γ, for Intratumoral Injection Alone and in Combination with Immune Checkpoint Blockade
Impact of SWI/SNF complex mutations in patients with non-small cell lung cancer treated with immune checkpoint inhibitors: Immuno-oncology biomarker study in LC-SCRUM-Japan
Overall survival modeling and association with serum biomarkers in durvalumab-treated patients with head and neck cancer
Cabozantinib (cabo) combined with durvalumab (durva) in gastroesophageal (GE) cancer and other gastrointestinal (GI) malignancies: Preliminary phase Ib CAMILLA study results
Improving Care for Patients with Stage III/IV NSCLC: Learnings for Multidisciplinary Teams from the ACCC National Quality Survey
Phase II study of Durvalumab plus Total Neoadjuvant Therapy in locally advanced rectal cancer. The GEMCAD-1703 DUREC trial
Assessment of 5-methylcytosine and 5-hydroxymethylcytosine technologies in contrived ctDNA-like samples
Concordance of provider treatment patterns with NCCN oncology treatment guidelines (NCCN Guidelines®) for metastatic non-small cell lung cancer (mNSCLC)
89Zr-durvalumab PD-L1 PET in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN)
SAKK 16/14: Anti-PD-L1 antibody durvalumab (MEDI4736) in addition to neoadjuvant chemotherapy in patients with stage IIIA(N2) non-small cell lung cancer (NSCLC)—A multicenter single-arm phase II trial.
Phase 1/2 study to evaluate systemic durvalumab + intraperitoneal (IP) ONCOS-102 in patients with peritoneal disease who have epithelial ovarian (OC) or metastatic colorectal cancer (CRC): Interim phase 1 clinical and translational results
Phase I Study of Radiotherapy (RT) & Durvalumab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) & Follicular Lymphoma (FL): The RaDD Study
Initial analyses of a Phase I/II trial of Durvalumab (D) plus tremelimumab (T) and stereotactic body radiotherapy (SBRT) for oligometastatic head and neck carcinoma
Non-pneumonitis immune-mediated Adverse Events (imAEs) with durvalumab in patients with unresectable, Stage III NSCLC (PACIFIC)
Contemporary management and associated outcomes of 3,151 patients with stage III non-small cell lung cancer (NSCLC) in a real-world setting: Results of KINDLE, a multi-country observational study
A phase 1b, open-label, dose escalation trial of naptumomab estafenatox (NAP) in combination with durvalumab (MEDI4736) in subjects with selected advanced or metastatic solid tumors
Durvalumab ± tremelimumab + platinum-etoposide in first-line extensive-stage SCLC (ES-SCLC): Updated Results from the phase III CASPIAN study.
A phase 1b/2, open-label study of tivozanib in combination with durvalumab in subjects with untreated advanced hepatocellular carcinoma
PrE0505: Phase II multicenter study of anti-PD-L1, durvalumab, in combination with cisplatin and pemetrexed for the first-line treatment of unresectable malignant pleural mesothelioma (MPM)—A PrECOG LLC study.
Durvalumab and tremelimumab in combination with FOLFOX in patients with RAS-mutated, microsatellite-stable, previously untreated metastatic colorectal cancer (MCRC): Results of the first intermediate analysis of the phase Ib/II MEDETREME trial.
A phase II trial of durvalumab (MEDI4736) and tremelimumab with chemotherapy in metastatic EGFR mutant non-squamous non-small cell lung cancer (NSCLC) following progression on EGFR tyrosine kinase inhibitors (TKIs) (ILLUMINATE)
A multicenter phase II trial of the combination cisplatin/docetaxel/durvalumab/tremelimumab as single-cycle induction treatment in locally advanced HNSCC (CheckRad-CD8 trial)
Long-term survival of combined ablation therapy and tremelimumab with or without durvalumab in advanced hepatocellular carcinoma
DURTRERAD: A phase II open-label study evaluating feasibility and efficacy of durvalumab (D) and durvalumab and tremelimumab (DT) in combination with radiotherapy (RT) in non-resectable locally advanced HPV-negative HNSCC – results of the preplanned feasibility interim analysis
SWOG S1400F (NCT03373760): A phase II study of durvalumab plus tremelimumab for previously treated patients with acquired resistance to PD-1 checkpoint inhibitor therapy and stage IV squamous cell lung cancer (Lung-MAP Sub-study)
Phase II trial of durvalumab plus tremelimumab with concurrent radiotherapy as a bladder-sparing therapy in patients with localized muscle invasive bladder cancer: A SOGUG study.
CCTG BR.34: A randomized trial of durvalumab and tremelimumab +/- platinum-based chemotherapy in patients with metastatic (Stage IV) squamous or nonsquamous non-small cell lung cancer (NSCLC).
DUTRENEO Trial: A randomized phase II trial of DUrvalumab and TREmelimumab versus chemotherapy as a NEOadjuvant approach to muscle-invasive urothelial bladder cancer (MIBC) patients (pts) prospectively selected by an interferon (INF)-gamma immune signature.
MONARCH 2: subgroup analysis of patients receiving first line endocrine therapy for HR+, HER2- advanced breast cancer
ALTERNATE: Neoadjuvant endocrine treatment (NET) approaches for clinical stage II or III estrogen receptor-positive HER2-negative breast cancer (ER+ HER2-BC) in postmenopausal (PM) women: Alliance A011106
PARSIFAL: A randomized, multicenter, open-label, phase II trial to evaluate palbociclib in combination with fulvestrant or letrozole in endocrine-sensitive patients with estrogen receptor (ER)[+]/HER2[-] metastatic breast cancer.
Maintenance olaparib plus bevacizumab (bev) after platinum-based chemotherapy plus bev in patients (pts) with newly diagnosed advanced high-grade ovarian cancer (HGOC): Efficacy by BRCA1 or BRCA2 mutation in the Phase III PAOLA-1 trial
Olaparib treatment in patients (pts) with platinum-sensitive relapsed (PSR) ovarian cancer (OC) by BRCA mutation (BRCAm) and homologous recombination deficiency (HRD) status:Phase II LIGHT study
Real-world clinical effectiveness and safety of olaparib monotherapy in HER2-negative gBRCA-mutated metastatic breast cancer: Phase 3b LUCY interim analysis
Olaparib maintenance monotherapy for non-germline BRCA1/2-mutated platinum-sensitive relapsed ovarian cancer patients: Phase IIIb OPINION interim data
Impact of olaparib vs physician’s choice of new hormonal agent (pcNHA) on burden of pain in metastatic castration-resistant prostate cancer (mCRPC): PROfound
POLO: Radiologic assessment of the impact of maintenance olaparib in patients (pts) with metastatic pancreatic cancer (mPaC)
Olaparib sensitivity in metastatic pancreatic cancer (mPaC) involving a wide spectrum of germline BRCA1 and BRCA2 mutations
POLO: Quality-adjusted (QA) progression-free survival (PFS) and patient (pt)-centered outcomes with maintenance olaparib in pts with metastatic pancreatic cancer (mPaC)
Health-related quality of life (HRQoL) for olaparib versus enzalutamide or abiraterone in metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene alterations: PROfound
Use of clinical classification software to differentiate good versus poor prognostic patients with ovarian cancer: A SEER-Medicare database analysis from the viera study
Will oncologists and patients make trade-offs between efficacy and toxicities in first-line treatment of advanced HER2 negative breast cancer?
DNA Damage Repair (DDR) gene mutations (mut) are predictors of response to platinum-based chemotherapy in advanced pancreatic cancer (PC) patients (pts)
Olaparib monotherapy in pre-treated patients with BRCA1/2 alterations – results of a cohort in the DRUP trial
Population adjusted indirect comparison of maintenance PARP inhibitor with or without bevacizumab versus bevacizumab in women with newly diagnosed ovarian cancer
NCI protocol 10250 - A phase II study of temozolomide and olaparib for the treatment of advanced uterine leiomyosarcoma
Phase II study of olaparib in malignant mesothelioma (MM) to correlate efficacy with germline and somatic mutations in DNA repair genes
Olaparib (O) in patients (pts) with pancreatic cancer with BRCA1/2 inactivating mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study
Olaparib (O) in patients (pts) with prostate cancer with BRCA1/2 inactivating mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study
Efficacy and safety of olaparib according to age in BRCA-1/2 mutated patients with recurrent platinum-sensitive ovarian cancer – analysis of the phase III SOLO2 (AGO-OVAR 2.23 / ENGOT-Ov21) study
A randomised phase II trial of olaparib maintenance versus placebo monotherapy in patients with chemosensitive advanced non-small cell lung cancer
Using oral morphine equivalent values to track the analgesic effect of treatments in clinical trials.
RADIOPARP: A Phase I of Olaparib with Radiation Therapy (RT) in Patients with Inflammatory, Loco-regionally Advanced or Metastatic triple negative breast cancer (TNBC) or Patient with Operated TNBC with Residual Disease: preliminary results
Patterns of progression and subsequent management of patients with BRCA1/2 mutated platinum-sensitive recurrent epithelial ovarian cancer (EOC) progressing on olaparib or placebo: the SOLO2/ENGOT Ov-21 trial
Concordance between CA-125 and RECIST progression (PD) in patients with germline BRCA-mutated platinum-sensitive, relapsed ovarian cancer treated with a PARP inhibitor (PARPi) as maintenance therapy after response to chemotherapy.
Olaparib as salvage treatment for advanced germ cell tumors after chemotherapy failure:results of the open-label, single-arm, IGG-02 phase II trial
Laboratory cross-comparison of tumor BRCA1/2analysis in a multicenter epithelial ovarian cancer series: the BORNEO GEICO 60-0 study
Fatigue in long-term survivors with ovarian cancer: Results of Expression VI – Carolin meets HANNA – Holistic Analysis of Long-term survival with Ovarian Cancer: the international NOGGO, ENGOT and GCIG survey
Final overall survival (OS) results from SOLO2/ENGOT-ov21: A phase III trial assessing maintenance olaparib in patients (pts) with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation.
A phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinum-based chemotherapy in recurrent platinum-sensitive ovarian cancer.Retrospective cohort study of real world treatment patterns and overall survival in patients with chronic lymphocytic leukemia in Ontario, Canada
Cediranib in combination with olaparib in patients without a germline BRCA1/2 mutation with recurrent platinum-resistant ovarian cancer: Phase IIb CONCERTO trial
Preliminary efficacy data of platinum-pretreated small cell lung cancer (SCLC) cohort of NCI 9881 study: A phase 2 study of cediranib in combination with olaparib in advanced solid tumors
DUO-E/GOG-3041/ENGOT-EN10: A randomized Phase III trial of first-line carboplatin and paclitaxel in combination with durvalumab, followed by maintenance durvalumab with or without olaparib, in patients with newly diagnosed advanced or recurrent endometrial cancer
Molecular correlates of response to preoperative olaparib alone or with cisplatin or with durvalumab in head and neck squamous cell carcinoma (HNSCC): A Hellenic Cooperative Oncology Group study
A Signal Seeking Trial of Olaparib and Durvalumab in Homologous Repair Deficient Tumours - A Substudy of the Cancer Molecular Screening and Therapeutics (MoST) program
Clinical performance of a comprehensive novel liquid biopsy test for identifying non-small cell lung cancer (NSCLC) patients for treatment with osimertinib
Real-world outcomes among patients with epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors versus immunotherapy or chemotherapy in first-line setting
A Phase II Study of Osimertinib for Patients with Radiotherapy-naïve CNS Metastasis of Non-Small Cell Lung Cancer harboring EGFR mutations: the OCEAN Study (LOGIK 1603/WJOG 9116L)
Final analysis of a phase II, open label, randomized study of osimertinib versus osimertinib plus carboplatin/pemetrexed for patients with locally advanced or metastatic nonsmall cell lung cancer whose disease has progressed with previous EGFR-TKI and whose tumours harbour a T790M mutation (LOGIK1604/NEJ032A)
Concurrent osimertinib plus gefitinib for first-line treatment of EGFR-mutated non-small cell lung cancer (NSCLC)
An observational, multicentre, Prospective study to evaluate concordance of detecting EGFR mutation by circulating tumour free DNA versus tissues biopsy in NSCLC (CONCORDANCE)
Comprehensive cross-platform comparison of methodologies for non-invasive EGFR mutation testing: Results of the RING observational trial
SAVOIR: A Phase III study of savolitinib vs sunitinib in pts with MET-driven papillary renal cell carcinoma (PRCC)
MET status and treatment outcomes in papillary renal cell carcinoma (PRCC): Pooled analysis of historical data
Phase I study of afatinib plus selumetinib in patients with KRAS mutation positive colorectal, non-small cell lung and pancreatic cancer
Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: A randomized, phase 2, multicenter, open-label study (DESTINY-Gastric01)
Trastuzumab deruxtecan (T-DXd; DS-8201) in combination with pembrolizumab in patients with advanced/metastatic breast or non-small cell lung cancer (NSCLC): A phase 1b, multicenter, study
Trastuzumab deruxtecan for HER2-positive metastatic breast cancer: DESTINY-Breast01 subgroup analysis
Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-mutated metastatic non-small cell lung cancer (NSCLC): Interim results of DESTINY-Lung01
A phase II, multicenter, open-label study of trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): DESTINY-CRC01
Real-world effectiveness of post–T-DM1 treatments in HER2-positive metastatic breast cancer: KBCSG-TR1917 observational study
Real-world study of the treatments following trastuzumab-emtansine for HER2-positive metastatic breast cancer: A multi-central cohort study (WJOG12519B)
Multicenter phase II study of trastuzumab deruxtecan (DS-8201) for HER2-positive unresectable or recurrent biliary tract cancer: HERB trial.